I mprovement in vascular endothelial function is widely cited as a beneficial effect of hormone replacement therapy (HRT). Women with type 2 diabetes (T2DM) are at increased cardiovascular risk and have impaired endothelial function. Any benefits of HRT on endothelial function in this group are of particular interest.
Introduction
The vascular endothelium plays a key role in atherosclerosis, regulating vascular tone, fibrinolysis and monocyte binding. 1 Endothelial dysfunction has been demonstrated in type 2 diabetes (T2DM) and contributes to increased cardiovascular risk. [2] [3] [4] [5] [6] Pre-menopausal women are relatively protected from cardiovascular disease but appear to lose this protection progressively following the menopause. T2DM is a potent cardiovascular risk factor, abrogating physiological coronary heart disease (CHD) protection in non-diabetic pre-menopausal women. 7 This CHD protection in non-diabetic women may be mediated, at least in part, by a protective effect of pre-menopausal hormones on the vascular endothelium. In keeping with this suggestion, increased forearm vascular resistance has been demonstrated in postmenopausal women compared with age-and BMI-matched pre-menopausal controls. 8 Furthermore, acute oestrogen administration has been widely reported to augment nitric oxide-mediated endothelium-dependent vasodilatation. [9] [10] [11] [12] [13] [14] These observations have led to the hypothesis that longer-term hormone replacement therapy may exert beneficial effects on the vascular endothelium. In non-diabetic women, several studies using high-resolution brachial ultrasound and one study using forearm plethysmography have reported improvements in endothelium-dependent vasodilatation with HRT. [15] [16] [17] [18] [19] However, uncertainty remains about the effect of longer-term HRT on endothelial function in women with T2DM: one observational study 20 and one 'before and after' study from our group 21 have reported beneficial effects of HRT on endothelium-dependent vasodilatation, while one randomised, placebo-controlled trial of unopposed conjugated equine oestrogen (0.625 mg) reported no benefit. 22 Despite the reported benefits of HRT on endothelial function, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol, two major randomised con-ORIGINAL ARTICLE
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trolled trials of conjugated equine oestrogen (0.625 mg) and medroxyprogesterone acetate (2.5 mg) have failed to demonstrate beneficial effects on cardiovascular events: the Heart and Estrogen/progestin Replacement Study (HERS) 23 (secondary prevention) reported a small increase in cardiovascular events in the first year of HRT but no overall effect over five years; the Women's Health Initiative (WHI) study 24 (primary prevention) showed a small but statistically significant increase in cardiovascular disease with HRT over five years. Diabetes was pre-specified for subgroup analysis in both studies, and results were similar in diabetic and in nondiabetic women. 25, 26 These trials have led to a change in medical thinking on HRT, from a position of presumed benefit to one of possible harm. 27 As a result, current expert advice is to use HRT for symptomatic reasons only and to use as low a dose of oestrogen as possible. This advice is supported by an observational study in women with T2DM in which low-dose, but not high-dose, oestrogen preparations were associated with reduced cardiovascular risk. 28 One potential explanation for apparent discrepancies between the results of large-scale, randomised clinical trials and smaller-scale studies based on surrogate end points is the HRT preparation examined. We have previously demonstrated, in women with T2DM, that transdermal oestradiol (80 µg twice weekly) in combination with oral norethisterone acetate (1 mg) had no effect on glucose metabolism, lipid metabolism or inflammation. 21 We then investigated the effects of lower-dose oral oestradiol in combination with oral norethisterone acetate in postmenopausal women with T2DM and now report results from a randomised, placebo-controlled trial of oral 17β oestradiol (1 mg) and norethisterone (0.5 mg) on parameters reflecting both large and small vessel function in these women (pulse wave velocity and ex vivo resistance artery function).
Subjects and methods

Subjects
All subjects were postmenopausal (more than one year from last menstrual period), aged below 70 years and had T2DM as defined by American Diabetes Association (1997) criteria. Subjects were eligible if they were on stable oral hypoglycaemic therapy and/or diet for at least three months prior to study. Exclusion criteria were poor glycaemic control (HbA 1C > 10%), severe fasting hypertriglyceridaemia (> 7.0 mmol/L), serum creatinine > 120 µmol/L, blood pressure > 160/110 mmHg, HRT use within the previous two years, insulin therapy, or other standard contraindication to HRT. Subjects were recruited from the Diabetes Centres of North Glasgow University Hospitals NHS Trust.
All subjects gave informed consent and the study had approval from the relevant hospital ethical review committees. An option was given on the consent form to opt out of the gluteal biopsy while undergoing all other study assessments.
Study design
Subjects were randomly assigned to oral 17β oestradiol (1 mg) and norethisterone acetate (0.5 mg) (Kliovance, Novo Nordisk) or to matching placebo in a double-blind manner in blocks of six, stratified for the presence or absence of hypertension. All subjects underwent baseline assessment with fasting blood samples and pulse wave velocity, as detailed below. Twenty-four subjects had studies of resistance artery function ex vivo performed for assessment of endothelial function. Arteries were dissected from biopsied gluteal fat, as described below. All assessments were repeated after three months of treatment with oral 17β oestradiol (1 mg) and norethisterone (0.5 mg) or with matching placebo.
Pulse wave velocity
Pulse wave velocity (PWV) was measured in the left (nondominant) arm in a temperature-controlled room at 24°C following a fast from 10 p.m. the previous evening (free water intake was allowed). All subjects omitted any oral hypoglycaemic agents on the morning of study but took their other prescribed medications. Brachial artery PWV was derived from pulse transit time and the distance travelled between carotid and radial arteries (PWV = distance [m]/ transit time [s]), calculated using an automated device (Complior, Colson France). A TY-306 pressure transducer (Fukuda Co.) was used to record the pressure /flow wave. Twenty recordings were made and the average PWV calculated. The intra-subject between-day coefficient of variation in our hands using this technique is 7.6%. 29 
Myography
Gluteal biopsy With the subject lying prone, one buttock was exposed and the area was sterilised with iodine. Lignocaine 1% was instilled subcutaneously, anaesthetising an area 4 cm x 2 cm. An elliptical incision was made and a 3 cm x 0.75 cm segment of skin and adipose tissue was removed. The skin was then sutured (sutures were removed seven days later). The biopsy was placed in 0.9% saline and transported directly to the laboratory for preparation.
Carbachol (muscarinic agonist), N G -Nitro-L-arginine methyl ester (L-NAME, substrate inhibitor of nitric oxide synthase), U-46619 (thromboxane mimetic) and indomethacin (all supplied by Sigma (Poole, UK)) were made up as fresh solutions in physiological salt solution (PSS). (Its composition is NaCl 118.4, KCl 4.7, MgSO 4 H 2 0 1.2, NaHCO 3 24.9, CaCl 2.5, glucose 11.1, and EDTA 0.023 mM.)
Preparation of arteries
Resistance-sized arteries (200-400 µm diameter and 2 mm in length) were dissected from the biopsied fat and mounted as ring preparations on two 40 µm stainless steel wires in a four-channel small vessel myograph (Danish MyoTechnology, Aarhus, Denmark), according to standard procedures in our laboratory. 30 One wire was attached to a force transducer and the other to a micrometer. Vessels were bathed in PSS and gassed with a mixture of 5% CO 2 and 95% 0 2 throughout the experiment. The temperature was maintained at 37°C and pH at 7.4. Normalisation was as described in detail elsewhere. 31 Myography protocol Following normalisation, vessels were maintained in PSS at ORIGINAL ARTICLE VOLUME 1 ISSUE 2 . OCTOBER 2004 37°C for a further 60 minutes. They were then exposed twice to KPSS (PSS solution with KCl substituted for NaCl on an equimolar basis) and subsequently incubated with PSS for 30 minutes; a cumulative concentration response curve (CRC) to U-46619 (10 -9 M to 3x10 -5 M) was then conducted. If vessels did not contract to KPSS or U-46619, or showed no relaxation to carbachol, they were discarded. After a further 30-minute incubation, a plateau contraction was obtained (10 -6 U-46619) before a CRC to carbachol (10 -9 M to 3 x 10 -5 M). Following a 30-minute washout period, vessels were incubated for 30 minutes with L-NAME (10 -4 M) and indomethacin (10 -5 M) before a further CRC to carbachol was conducted (10 -9 M to 3 x 10 -5 M).
Laboratory assays
Adhesion molecules VCAM-1 (Parameter Human sVCAM-1 Immunoassay, R&D systems Inc., Oxon, UK) and ICAM-1 (Parameter Human sICAM-1 Immunoassay, R&D systems Inc., Oxon, UK) were assayed using commercially available enzyme-linked immunosorbent assays. The intra-and interassay coefficients of variation were < 7% and < 10%, respectively, over the sample concentration range. The detection limit of the assay was 0.5 ng/ml.
Statistics
Statistical analysis was performed using Minitab 13.1 (State College, PA). Baseline data are expressed as mean +/-SD or median (Q1, Q3), if not normally distributed. Results after treatment are expressed as percentage change from baseline, except for blood pressure which is expressed as an absolute change from baseline in mmHg. Differences between the groups were assessed using a two-sample t test (normally distributed data) or Mann-Whitney U test (nonparametric data). A p value of less than 0.05 was considered statistically significant. Ninety-five percent confidence intervals for differences between groups in mean percentage change from baseline are given.
Results
Clinical features
Thirty women gave informed consent and entered the study. Two were withdrawn -one taking HRT following a cerebrovascular accident and one taking placebo following leg swelling. Twelve women in each group had gluteal fat biopsies and the myography protocol was successfully completed in 10 subjects from each group.
Subjects had a mean age of 62 years and the majority were overweight, with a mean body mass index (BMI) of 33 kg/m 2 . Table 1 indicates the characteristics of the women as randomised. Identical numbers of subjects from each group were hypertensive and on treatment. Only one subject was ORIGINAL ARTICLE Sulphonylurea alone (n) 3 4 Metformin alone (n) 5 2
Combination OHAs (n) 3 5 Statin (n) 5 4
Previous IHD/CVA (n) 0 1
Current smoker (n) 3 3
Ex-smoker (n) 1 1
Key: BMI = body mass index; OHA = oral hypoglycaemic agent; IHD = ischaemic heart disease; CVA = cerebrovascular accident DIABETES AND VASCULAR DISEASE RESEARCH Key: CI = confidence intervals; SBP = systolic blood pressure; DBP = diastolic blood pressure; PWV = pulse wave velocity; VCAM = vascular cell adhesion molecule; ICAM = intracellular adhesion molecule known to have either ischaemic heart disease or cerebrovascular disease at entry to the study. Smoking rates and prescription rates of statins and oral hypoglycaemic agents were similar in both groups.
Blood pressure/pulse wave velocity
Blood pressure and pulse wave velocity fell slightly during the course of the study, with no differences between women allocated to HRT or placebo (table 2) .
Myography results
There was no difference in baseline response to carbachol in women allocated to HRT or placebo (table 3) . CRCs were successfully performed to carbachol at baseline and after three months' treatment in 10 subjects from the HRT group and eight subjects from the placebo group. Repeat CRCs to carbachol in the presence of L-NAME/ indomethacin were obtained in eight vessels from women allocated to HRT and seven from women allocated to placebo. Figure 1 shows the CRC for carbachol following three months' treatment. Sensitivity to carbachol, as assessed by the pD 2 (-logEC50), was similar in both HRTand placebo-treated groups and did not change during the course of the study (table 3) . Maximum contractile response to U-46619 was similar in both groups and was unaffected by treatment (table 3) . Maximum relaxation to carbachol was also similar in both groups, and was unaffected by treatment (table 3) . The CRC to carbachol shifted to the right with the addition of L-NAME and indomethacin by a similar amount for both HRT-and placebo-allocated groups (figure 2). Mean plateau constriction was 20.7 mN/m 2 after three months' HRT compared with 23.3 mN/m 2 in the placebo-treated group. This difference was not statistically significant (95% CI -7.7 to +2.5 mN/m 2 ). There was no difference at baseline between HRT and placebo groups with regard to shift in pD 2 , maximum contractile response to U-46619 or maximum relaxation to carbachol (table 3) and no differences in change in these parameters following three months of HRT or placebo was detected.
Cell adhesion molecules -results
VCAM-1 and ICAM-1 levels fell during the course of the study to a similar extent in HRT-and placebo-treated groups (table 2) .
Discussion
In the present study we used a randomised, placebo-controlled design in an effort to examine the effect of continuous combined oral HRT on pulse wave velocity and resistance artery endothelial function in women with T2DM. We detected no effect of three months' oral 17β oestradiol (1 mg) and norethisterone (0.5 mg) on brachial pulse wave velocity, endothelium-dependent relaxation of resistance vessels or markers of endothelial function (VCAM-1 and ICAM-1). Pulse wave velocity is an integrated index of large vessel structure and function, including endothelial function; it has been shown independently to predict cardiovascular risk in T2DM, and to increase in the postmenopausal years. 30, 32 We detected no effect of three months' therapy with continuous oral 17β oestradiol (1 mg) and norethisterone (0.5 mg) on brachial pulse wave velocity. Although we studied relatively small numbers of women, we found no evidence of a trend towards any beneficial effect of HRT. The power to detect a 15% change in pulse wave velocity with α=0.05 was 76%, based on mean pulse wave velocity of 9.9 ms -1 with a standard deviation of 2.3 ms -1 and 15 subjects in each group.
The brachial artery is a muscular artery and may not reflect central arterial compliance. Nonetheless, these results are in keeping with a previous open-label, cross-over study of conjugated equine (o)estrogen (CEE) 0.625 mg and medroxyprogesterone acetate (MPA) 2.5 mg in women with T2DM that found no effect on aorto-femoral pulse wave velocity. 33 Previous studies conducted in non-diabetic women have reported conflicting findings: one open-label study of oral sequential combined HRT found a reduction in pulse wave velocity after three months' treatment, 34 while another double-blind, placebo-controlled study using 2 mg oestradiol and 1 mg norethisterone reported no effect. 35 It must, therefore, be concluded that in women with T2DM there is no evidence to date that HRT increases arterial compliance while in non-diabetic women the evidence is conflicting. Improvement in endothelium-dependent vasodilatation is commonly cited as a beneficial effect of HRT. Our study examined longer-term effects (over three months) of continuous oral 17β oestradiol (1 mg) and norethisterone (0.5 mg) on small resistance vessels' (diameter 200-400 µm) function ex vivo in women with T2DM, using wire myography. We found no evidence of any effect on vasorelaxation to carbachol, an endothelium-dependent vasodilator. The study was powered primarily to assess sensitivity to carbachol using pD 2 (-logEC50). The power of the study to detect a 10% change in pD 2 was over 90% with α=0.05, based on a mean pD 2 of 6.5, standard deviation of 0.5 and 10 subjects in each myography group. Similar sized studies using the same techniques from our research group have detected differences in vascular function in congestive heart failure and polycystic ovarian syndrome. 29, 36 Indomethacin and L-NAME produced similar shifts in dose-response curves in both HRTtreated and placebo-treated groups, suggesting that HRT had no effect on cyclo-oxygenase or nitric oxide-dependent vasodilatation.
These results are in keeping with a randomised, placebocontrolled trial of unopposed 0.625 mg conjugated equine oestrogen in women with T2DM that found no effect on flow-mediated dilatation. 22 They contrast, however, with one previous observational study of HRT 20 and a 'before and after' study from our own group of transdermal oestradiol combined with oral norethisterone acetate in women with T2DM. 37 The observational study 20 used laser Doppler flowmetry to assess small vessel endothelial function, but its design makes the results difficult to interpret. It is recognised that women who choose to take HRT are of higher socioeconomic class and may exhibit different health-seeking behaviour, leading to potential systematic bias in observational studies. 38 Our 'before and after' study of transdermal oestradiol combined with oral norethisterone acetate found potentially beneficial effects on resistance vessel endothelial function using a similar technique to that employed in this study. The contrast with the present results may have been due to the oestrogen used (transdermal [80 µg twice weekly] versus oral 17β oestradiol [1 mg]) or to differences in norethisterone dose (1 mg versus 0.5 mg). However, differences in experimental design cannot be discounted.
A further possible explanation of the negative results is that the heterogeneity of oral hypoglycaemic agents used may have masked any effect of HRT on endothelial function. Against this, both of the studies referred to above included women on sulphonylurea therapy. 20, 37 Also, in two recent cross-sectional studies detailed vascular assessments were performed in subjects with type 2 diabetes and hypertension in whom sulphonylurea and statin therapy were continued. 39, 40 In one study the use of oral hypoglycaemic agents did not influence response to acetylcholine. 39 With regard to concerns that sulphonylureas may affect endotheliumdependent hyperpolarising factor (EDHF), it is becoming increasingly clear that the effects of EDHF are mediated by calcium-activated potassium channels while sulphonylureas affect potassium-ATP channels. 41 In support of our findings, the only previous randomised, placebo-controlled study of HRT in women with type 2 diabetes, in which sulphonylureas were discontinued before entering the study, found no effect of oral 0.625 mg CEE on endothelium-dependent vasodilation. 22 Since both the present study and the only previous one of a similarly robust design 22 found no effect, it is safe to conclude that HRT does not affect endothelial dysfunction in these women.
The negative results in women with T2DM contrast with most longer term in vivo studies in non-diabetic women; [15] [16] [17] [18] [19] 42 These studies used a variety of HRT preparations, including transdermal oestradiol, continuous combined oral HRT and unopposed oestrogen, in both conventional and low doses. One previous study in non-diabetic women reported beneficial effects on flow-mediated dilatation in conduit arteries and on plasma nitrite/nitrate concentrations using an identical preparation to that used in this study, though the relevance of these parameters to small resistance artery function is not certain. 43 This study was not placebo-controlled: rather, subjects were randomised to genistein (a tyrosine kinase inhibitor) or oral 17β oestradiol (1 mg) and norethisterone (0.5 mg).
Since beneficial effects of HRT on endothelium-dependent vasodilatation in non-diabetic women have been reported for both combined HRT and low-dose HRT (including preparations identical to those used in this study), it is unlikely that the negative results reported here are due to the low dose used or the combination with a progestagen. In non-diabetic animals and human cell culture models acute administration of oestrogen causes rapid vasodilatation by a non-genomic, PI-3 kinase and PKB(Akt)-dependent mechanism. 14,44-47 PI-3 kinase and PKB(Akt) are also important insulin signalling molecules and have been implicated as key determinants of human insulin sensitivity. 48, 49 Although the explanation for a lack of effect of HRT in women with T2DM cannot be determined from the present study, it is possible that factors mediating resistance to insulin signalling also block endothelial effects of oestrogen. 49 Inflammation is now recognised to be of major importance in atherosclerosis; pro-inflammatory effects of CEE and MPA have been hypothesised to be responsible for the negative results of the HERS and WHI trials. 50 Cell adhesion molecules, which tether circulating inflammatory cells to the endothelium, may play an important role in vascular inflammation. 51, 52 Levels of VCAM-1 and ICAM-1 decreased during the course of the study, but there was no significant difference between HRT-and placebo-treated groups. These results are in keeping with previous randomised, placebocontrolled studies of unopposed CEE (0.625 mg) 22 and combined CEE (0.625 mg)/MPA (2.5 mg) 53 in women with T2DM, but contrast with studies, including randomised placebo-controlled studies, in non-diabetic women using a variety of preparations of unopposed oestrogen and combined HRT. [54] [55] [56] [57] [58] [59] [60] Nitric oxide is well known to downregulate expression of cell adhesion molecules. [61] [62] [63] Koh et al. hypothesise that the reason for the difference between diabetic and non-diabetic women may therefore relate to the lack of effect of HRT on nitric oxide bioavailability in women with type 2 diabetes. 22 The present study suggests that three months' low-dose combined oral HRT (17β oestradiol [1 mg] and norethisterone [0.5 mg]) does not improve endothelial function in postmenopausal women with T2DM. The results contrast with those for non-diabetic women, in whom acute and longer-term effects of oestrogen and combined HRT are reported to augment endothelium-dependent vasodilatation. The reason for the discrepancy between diabetic and non-diabetic women with T2DM is not clear but may relate to insulin resistance. Further research into the differences in response between diabetic and non-diabetic women to oestrogen in the vascular endothelium may provide valuable insights into the reasons why T2DM is such a potent cardiovascular risk factor for pre-menopausal women. The present results are in keeping with current recommendations that, for postmenopausal women with T2DM, aggressive evidence-based treatment of modifiable cardiovascular risk factors should remain the mainstay of treatment, with postmenopausal HRT reserved for symptom control alone.
